Incorporating Monte Carlo simulation into physiologically based pharmacokinetic models using advanced continuous simulation language (ACSL): a computational method.
暂无分享,去创建一个
R S Yang | R. S. Thomas | R S Thomas | W E Lytle | T J Keefe | A A Constan | T. Keefe | R. S. Yang | A. Constan | W. Lytle | R. S. Yang
[1] L. Lowry,et al. Biological monitoring IV: Measurements in urine , 1989 .
[2] C J Portier,et al. Variability of safe dose estimates when using complicated models of the carcinogenic process. A case study: methylene chloride. , 1989, Fundamental and applied toxicology : official journal of the Society of Toxicology.
[3] B. Allen,et al. Evaluation of uncertainty in input parameters to pharmacokinetic models and the resulting uncertainty in output. , 1989, Toxicology letters.
[4] J. Filliben. The Probability Plot Correlation Coefficient Test for Normality , 1975 .
[5] R H Reitz,et al. Physiologically based pharmacokinetic modeling with methylchloroform: implications for interspecies, high dose/low dose, and dose route extrapolations. , 1988, Toxicology and applied pharmacology.
[6] R C Spear,et al. Structure and parameterization of pharmacokinetic models: their impact on model predictions. , 1992, Risk analysis : an official publication of the Society for Risk Analysis.
[7] Robert V. O'Neill,et al. Application of error analysis to a Marsh Hydrology Model , 1980 .
[8] L. Lowry,et al. Horizons: Biological Monitoring IV: Measurements in Urine , 1989 .
[9] R A Corley,et al. Physiologically based pharmacokinetics of 2-butoxyethanol and its major metabolite, 2-butoxyacetic acid, in rats and humans. , 1994, Toxicology and applied pharmacology.
[10] M E Andersen,et al. Development of a physiologically based pharmacokinetic model for chloroform. , 1990, Toxicology and applied pharmacology.
[11] H A el-Masri,et al. The use of physiologically-based pharmacokinetic/pharmacodynamic dosimetry models for chemical mixtures. , 1995, Toxicology letters.
[12] John F. Young,et al. A physiologically based pharmacokinetic computer model for human pregnancy. , 1994, Teratology.
[13] F Y Bois,et al. An analysis of exposure rate effects for benzene using a physiologically based pharmacokinetic model. , 1992, Regulatory toxicology and pharmacology : RTP.
[14] Christopher J. Portier,et al. Variability of safe dose estimates when using complicated models of the carcinogenic process. A case study: methylene chloride. , 1989 .
[15] D G Gray,et al. A physiologically based pharmacokinetic model for methyl mercury in the pregnant rat and fetus. , 1995, Toxicology and applied pharmacology.
[16] L S Birnbaum,et al. A physiological model for simulation of benzene metabolism by rats and mice. , 1989, Toxicology and applied pharmacology.
[17] M E Andersen,et al. A physiologically based toxicokinetic description of the metabolism of inhaled gases and vapors: analysis at steady state. , 1981, Toxicology and applied pharmacology.
[18] C C Travis,et al. Pharmacokinetics of benzene. , 1990, Toxicology and applied pharmacology.
[19] H J Clewell,et al. Incorporation of pharmacokinetics in noncancer risk assessment: example with chloropentafluorobenzene. , 1994, Risk analysis : an official publication of the Society for Risk Analysis.
[20] H J Clewell,et al. A physiologically based simulation approach for determining metabolic constants from gas uptake data. , 1986, Toxicology and applied pharmacology.
[21] H. Leung,et al. Use of physiologically based pharmacokinetic models to establish biological exposure indexes. , 1992, American Industrial Hygiene Association journal.
[22] R C Spear,et al. Mechanisms of benzene carcinogenesis: application of a physiological model of benzene pharmacokinetics and metabolism. , 1991, Toxicology letters.
[23] F. A. Smith,et al. Physiologically based pharmacokinetics and the risk assessment process for methylene chloride. , 1987, Toxicology and applied pharmacology.
[24] R. L. Zielhuis,et al. Phenol excretion as a measure of benzene exposure. , 1967, The Annals of occupational hygiene.
[25] R C Spear,et al. Modeling benzene pharmacokinetics across three sets of animal data: parametric sensitivity and risk implications. , 1991, Risk analysis : an official publication of the Society for Risk Analysis.
[26] D J Paustenbach,et al. A physiological pharmacokinetic description of the tissue distribution and enzyme-inducing properties of 2,3,7,8-tetrachlorodibenzo-p-dioxin in the rat. , 1990, Toxicology and applied pharmacology.
[27] D J Paustenbach,et al. A physiologically based pharmacokinetic model for inhaled carbon tetrachloride. , 1988, Toxicology and applied pharmacology.
[28] S. T. Sie,et al. THE MEASUREMENT OF PHENOL IN URINE BY GAS CHROMATOGRAPHY AS A CHECK ON BENZENE EXPOSURE. , 1965, American Industrial Hygiene Association journal.
[29] R C Spear,et al. Comparison of three physiologically based pharmacokinetic models of benzene disposition. , 1991, Toxicology and applied pharmacology.
[30] R B Conolly,et al. Development of a physiologically based pharmacokinetic model describing 2-methoxyacetic acid disposition in the pregnant mouse. , 1995, Toxicology and applied pharmacology.
[31] R. S. Thomas,et al. Variability in biological exposure indices using physiologically based pharmacokinetic modeling and Monte Carlo simulation. , 1996, American Industrial Hygiene Association journal.
[32] M E Andersen,et al. A physiologically based pharmacokinetic model for 2,3,7,8-tetrabromodibenzo-p-dioxin (TBDD) in the rat: tissue distribution and CYP1A induction. , 1993, Toxicology and applied pharmacology.